

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 59029

Title: Unresectable esophageal cancer treated with multiple chemotherapies in combination with chemoradiotherapy: A case report

Reviewer's code: 03080579

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2020-08-27

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2020-12-04 08:29

Reviewer performed review: 2020-12-12 12:13

Review time: 8 Days and 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The manuscript described the successful case of an unresectable locally advanced T4 ESCC treated by additional CF chemotherapy after induction DCF followed by dCRT. And the authors suggested that additional CF chemotherapy could be one radical treatment option for residual ESCC after induction DCF followed by dCRT to avoid salvage surgery, especially for high-risk patients. The treatment course is clear and the result is encouraging. And the manuscript is well and concisely written. However, several points need to point out. 1.English editing is required. 2.In the section of History of past illness, the authors should provide the detailed treatment that the patient received before. 3.The pathological examination result should be described in detail. 4.In this case, induction chemotherapy with DCF followed by dCRT did not result in a CR for an initially unresectable locally advanced T4 ESCC, but a CR was finally achieved with two additional courses of CF chemotherapy. And in the authors' opinion, the dCRT played the key role or the two additional courses of CF chemotherapy did, in the whole course of treatment for the initially unresectable locally advanced T4 ESCC patient?

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 59029

Title: Unresectable esophageal cancer treated with multiple chemotherapies in combination with chemoradiotherapy: A case report

Reviewer's code: 03271092

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Chief Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2020-08-27

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2020-12-06 14:21

Reviewer performed review: 2020-12-13 12:41

Review time: 6 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input checked="" type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Currently, for patients with unresectable locally advanced esophageal squamous cell carcinoma, concurrent chemoradiotherapy has been clinically proven to significantly prolong survival compared to radiotherapy alone, and is therefore considered the standard treatment strategy. The standard treatment for locally advanced unresectable esophageal squamous cell carcinoma (SCC) is chemoradiotherapy with cisplatin and 5-fluorouracil (CF-RT). Considerable experimental data have proved that the effect of induction of esophageal squamous cell carcinoma combined with concurrent chemoradiotherapy is significantly better than that of concurrent chemoradiotherapy. Many large retrospective studies both at home and abroad have IV period esophageal squamous carcinoma of the radiation and chemotherapy curative effect analysis has made a conclusion: IV period esophageal squamous carcinoma recommended sequential chemotherapy after concurrent chemoradiation comprehensive treatment, can prolong the patient's overall survival time, improve the prognosis of patients. Therefore, this case report has no significant innovation or breakthrough in the treatment idea or the treatment drugs, but only verifies the effectiveness of the currently relatively recognized treatment methods.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 59029

Title: Unresectable esophageal cancer treated with multiple chemotherapies in combination with chemoradiotherapy: A case report

Reviewer's code: 03080579

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2020-08-27

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2021-02-21 01:57

Reviewer performed review: 2021-02-21 08:25

Review time: 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Accept